Latest Conference Articles

Patients with large B-cell lymphoma tended to have better quality of life that continued to improve over time after receiving Breyzani compared to those given standard of care.

Although patients treated with Lynparza after chemotherapy may experience side effects such as fatigue and nausea/vomiting, these symptoms resolved after treatment was completed in patients with high-risk early breast cancer.

A three-drug regimen was shown to lengthen the amount of time before cancer progressed to the central nervous system — known as central nervous system progression-free survival — in certain patients with breast cancer.

In recent trial results, a dose reduction of Xpovio (selinexor) was associated with longer progression-free survival and duration of response while also reducing side effects in patients with multiple myeloma.

The use of pyrotinib — an experimental drug — plus the chemotherapy capecitabine extended survival compared with Tykerb and capecitabine among patients with pretreated HER2-positive metastatic breast cancer.

Early-phase study results showed that treatment with a novel drug elicits promising outcomes in patients with advanced or metastatic triple-negative breast cancer.

Clinical trial results show that adding Keytruda to chemotherapy prior to surgery for triple-negative breast cancer can improve outcomes and hopefully “increase the chances for patients to be cured,” according to an expert.

The addition of Ibrance to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, according to final results of the phase 3 PALLAS trial.

Researchers hypothesized that metformin — a medication that helps lower insulin levels in patients with diabetes and is associated with inducing weight loss — might improve breast cancer outcomes.

The use of elacestrant, an investigational therapy, elicited a 30% reduction in the risk of disease progression or death compared with standard of care in a group of patients with estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.

Ibrance plus Faslodex improved progression-free survival in certain patients with metastatic breast cancer, compared with those who continued to receive an aromatase inhibitor.

Black race is associated with a 3.5-fold increased incidence of lymphedema in women with breast cancer treated with axillary lymph node dissection and radiotherapy, according to recent data.

View the full CURE Educated Patient Breast Cancer Summit Outside of Therapy Session on demand.

View the full CURE Educated Patient Breast Cancer Summit Novel Therapies Session on demand.

View the full CURE Educated Patient Breast Cancer Summit Multi-Disciplinary Approaches to Early-Stage Breast Cancer Session on demand.

View the full CURE Educated Patient Kidney Cancer Summit on demand.

View the full CURE® Educated Patient® Multiple Myeloma Summit in Partnership with Sylvester Comprehensive Cancer Center, University of Miami on demand.

View the full CURE Educated Patient MPN Summit on demand.

View the full CURE Educated Patient Lung Cancer Summit on demand.

View the full CURE Educated Patient Lung Cancer Summit on demand.

View the full CURE Educated Patient Lung Cancer Summit on demand.

View the full CURE Educated Patient Leukemia Summit on demand.

View the full CURE Educated Patient Skin Cancer Summit on demand.

The long-term follow-up data, according to one of the study’s authors from the Sarah Cannon Cancer Institute, demonstrate “a new benchmark for the standard of care” in the treatment of patients with unresectable stage 3 non-small cell lung cancer.

Treatment with aumolertinib was associated with prolonged survival in patients with advanced non-small cell lung cancer.

After long-term follow-up, the CAR-T cell therapy still boosted survival outcomes in patients with relapsed/refractory multiple myeloma, regardless of the number of prior lines of therapy received.

Previously treated patients with non-small cell lung cancer tended to have better responses with Retevmo than they did with prior treatments.

Treatment with a novel combination therapy was associated with increased efficacy among patients with aggressive relapsed or refractory B-cell non-Hodgkin lymphoma and was also well tolerated.

Adding Opdivo to treatment with Yervoy or chemotherapy improved survival, compared with chemotherapy alone in patients with unresectable and advanced esophageal cancer.

The addition of a novel drug to the chemotherapies gemcitabine and cisplatin significantly improved a survival outcome in patients with a rare form of head and neck cancer, compared with chemotherapy alone.